Timing tumor DNA tests after chemo: a small study
NCT ID NCT06141772
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measured how levels of circulating tumor DNA (ctDNA) change in the hours after the first round of chemotherapy in 24 people with diffuse large B cell lymphoma. The goal was to find the best time to take blood samples for monitoring the cancer. Researchers hope that a better understanding of ctDNA timing could improve how doctors track the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors know the best time to test for tumor DNA after chemotherapy, improving how they monitor the disease.
- What could go wrong
- This is a very small, completed study with only 24 participants. It is designed to gather information, not to test a new treatment, so it may not lead to any direct patient benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Henri Becquerel
Rouen, 76000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?